Transverse myelitis (TM) is a rare neurological condition wherein the spinal cord is inflamed. The adjective transverse implies that the spinal inflammation (myelitis) extends horizontally throughout the cross section of the spinal cord; the terms partial transverse myelitis and partial myelitis are sometimes used to specify inflammation that affects only part of the width of the spinal cord. TM is characterized by weakness and numbness of the limbs, deficits in sensation and motor skills, dysfunctional urethral and anal sphincter activities, and dysfunction of the autonomic nervous system that can lead to episodes of high blood pressure. Signs and symptoms vary according to the affected level of the spinal cord. The underlying cause of TM is unknown. The spinal cord inflammation seen in TM has been associated with various infections, immune system disorders, or damage to nerve fibers, by loss of myelin. As opposed to leukomyelitis which affects only the white matter, it affects the entire cross-section of the spinal cord. Decreased electrical conductivity in the nervous system can result.
Tetraplegia, also known as quadriplegia, is defined as the dysfunction or loss of motor and/or sensory function in the cervical area of the spinal cord. A loss of motor function can present as either weakness or paralysis leading to partial or total loss of function in the arms, legs, trunk, and pelvis. The paralysis may be flaccid or spastic. A loss of sensory function can present as an impairment or complete inability to sense light touch, pressure, heat, pinprick/pain, and proprioception. In these types of spinal cord injury, it is common to have a loss of both sensation and motor control.
A spinal cord injury (SCI) is damage to the spinal cord that causes temporary or permanent changes in its function. It is a destructive neurological and pathological state that causes major motor, sensory and autonomic dysfunctions.
The California Institute for Regenerative Medicine (CIRM) is a state agency that supports research and education in the fields of stem cell and gene therapies. It was created in 2004 after 59% of California voters approved California Proposition 71: the Research and Cures Initiative, which allocated $3 billion to fund stem cell research in California. In 2020 voters approved Proposition 14 that allocated additional funds to CIRM.
Central cord syndrome (CCS) is the most common form of cervical spinal cord injury (SCI). It is characterized by loss of power and sensation in arms and hands. It usually results from trauma which causes damage to the neck, leading to major injury to the central corticospinal tract of the spinal cord. CCS most frequently occurs among older persons with cervical spondylosis, however, it also may occur in younger individuals.
Neurocritical care is a medical field that treats life-threatening diseases of the nervous system and identifies, prevents, and treats secondary brain injury.
Posterior spinal artery syndrome(PSAS), also known as posterior spinal cord syndrome, is a type of incomplete spinal cord injury. PSAS is the least commonly occurring of the six clinical spinal cord injury syndromes, with an incidence rate of less than 1%.
MedStar National Rehabilitation Network is located in Washington, D.C., and specializes in treating persons with physical disabilities. The National Rehabilitation Hospital was founded in 1986 by Edward A. Eckenhoff, and is a member of the MedStar Health system, the Washington, D.C.-Baltimore region's largest non-profit healthcare organization.
Santa Clara Valley Medical Center, commonly known as Valley Medical Center or simply Valley Medical, is a prominent 731-bed public tertiary, teaching, and research hospital in San Jose, California. Located in the Fruitdale neighborhood of West San Jose, Valley Medical Center is the anchor facility of the Santa Clara County Health System, serving Santa Clara County. Valley Medical is home to numerous innovative research and care centers, such as the Rehabilitation Trauma Center, the only federally-designated spinal cord injury center in Northern California.
Magee Rehabilitation Hospital, part of Jefferson Health, founded in 1958, is a 96-bed specialty medical rehabilitation hospital providing physical and cognitive rehabilitation services. Magee's flagship facility is located in Center City Philadelphia. In addition to the main campus that offers comprehensive services for spinal cord injury, brain injury, stroke, orthopaedic replacement, amputation, pain management and work injury, Magee provides an expanding outpatient network serving the surrounding communities.
TIRR Memorial Hermann is a 134-bed rehabilitation hospital, rehabilitation and research center, outpatient medical clinic and network of outpatient rehabilitation centers in Houston, Texas that offers comprehensive physical, occupational, and speech therapy services to rehabilitate patients following traumatic brain or spinal injury or to those suffering from neurologic illnesses.
Rockcastle Regional Hospital and Respiratory Care Center is a not-for-profit acute and long-term care hospital located in Mt. Vernon, Kentucky. The facility primarily serves Rockcastle and surrounding counties with its 26-bed acute care facility, but receives referrals for its 143-bed ventilator facility nationwide It is an eleven-time winner of the Kentucky Hospital Association Quality Award and is accredited by the Joint Commission.
The Food and Drug Administration (FDA) approved the first clinical trial in the United States involving human embryonic stem cells on January 23, 2009. Geron Corporation, a biotechnology firm located in Menlo Park, California, originally planned to enroll ten patients with spinal cord injuries to participate in the trial. The company hoped that GRNOPC1, a product derived from human embryonic stem cells, would stimulate nerve growth in patients with debilitating damage to the spinal cord. The trial began in 2010 after being delayed by the FDA because cysts were found on mice injected with these cells, and safety concerns were raised.
Arthur L. Jenkins III is an American fellowship-trained neurosurgeon, co-director of the Neurosurgical Spine Program, and Director of Spinal Oncology and Minimally Invasive Spinal Surgery (MIS) Program at the Mount Sinai Hospital, New York. Additionally, he is an associate professor of Neurosurgery and of Orthopedic Surgery at the Mount Sinai School of Medicine. Dr. Jenkins has multiple patents and patent applications for spine-related implants and support systems, and is developing new minimally invasive treatments for patients with cancer that has spread to the spine. He is an innovator in the treatment of acute spinal cord injury as well as degenerative and congenital anomalies of the spine, taking a minimally invasive or minimal-impact approach where possible. He is board certified in Neurological Surgery and is licensed in New York and Connecticut.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.
Spinal cord injury without radiographic abnormality (SCIWORA) is symptoms of a spinal cord injury (SCI) with no evidence of injury to the spinal column on X-rays or CT scan. Symptoms may include numbness, weakness, abnormal reflexes, or loss of bladder or bowel control. Neck or back pain is also common. Symptoms may be brief or persistent. Some do not develop symptoms until a few days after the injury.
Spinal cord injury research seeks new ways to cure or treat spinal cord injury in order to lessen the debilitating effects of the injury in the short or long term. There is no cure for SCI, and current treatments are mostly focused on spinal cord injury rehabilitation and management of the secondary effects of the condition. Two major areas of research include neuroprotection, ways to prevent damage to cells caused by biological processes that take place in the body after the injury, and neuroregeneration, regrowing or replacing damaged neural circuits.
Odette Harris is a professor of neurosurgery at Stanford University and the Director of the Brain Injury Program for the Stanford University School of Medicine. She is the Deputy Chief of Staff, Rehabilitation at the VA Palo Alto Health Care System.
Spinal cord stroke is a rare type of stroke with compromised blood flow to any region of spinal cord owing to occlusion or bleeding, leading to irreversible neuronal death. It can be classified into two types, ischaemia and haemorrhage, in which the former accounts for 86% of all cases, a pattern similar to cerebral stroke. The disease is either arisen spontaneously from aortic illnesses or postoperatively. It deprives patients of motor function or sensory function, and sometimes both. Infarction usually occurs in regions perfused by anterior spinal artery, which spans the anterior two-thirds of spinal cord. Preventions of the disease include decreasing the risk factors and maintaining enough spinal cord perfusion pressure during and after the operation. The process of diagnosing the ischemic and hemorrhagic spinal cord stroke includes applying different MRI protocols and CT scan. Treatments for spinal cord stroke are mainly determined by the symptoms and the causes of the disease. For example, antiplatelet and corticosteroids might be used to reduce the risk of blood clots in ischaemic spinal stroke patients, while rapid surgical decompression is applied to minimize neurological injuries in haemorrhagic spinal stroke patients instead. Patients may spend years for rehabilitation after the spinal cord stroke.
Deepak Agrawal born 10 November 1970, is a professor neurosurgery at All India Institute of Medical Sciences, New Delhi is one of the top 10 surgeons in the neurosurgery. During his stint as chairman computerization, he reformed the ICT processes at AIIMS, New Delhi and also helped patients in All India Institute of Medical Sciences, New Delhi to get a Unique Health Identification (UHID), which documents their journey in the hospital. He also pioneered stem cell research in spinal cord injury in India and set up the Stem Cell translational research in Neuroscience LAB (SCRTN) at AIIMS, New Delhi.
